Published in Cancer Weekly, January 4th, 2005
In the study, six patients experienced objective clinical responses (two complete responses and four partial responses) out of a total of 56 patients with refractory or relapsed CD30-positive lymphomas, such as Hodgkin disease (HD) and anaplastic large cell lymphoma (ALCL). Overall, 43% of the patients experienced disease remission or stabilization, including the six patients with objective responses and 18 patients who experienced stable disease.
The updated results of the phase I and phase II portions of the ongoing clinical trial were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.